GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » YIFAN PHARMACEUTICAL CO LTD (SZSE:002019) » Definitions » Gross Profit

YIFAN PHARMACEUTICAL CO (SZSE:002019) Gross Profit : ¥2,116 Mil (TTM As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is YIFAN PHARMACEUTICAL CO Gross Profit?

YIFAN PHARMACEUTICAL CO's gross profit for the three months ended in Mar. 2024 was ¥628 Mil. YIFAN PHARMACEUTICAL CO's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ¥2,116 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. YIFAN PHARMACEUTICAL CO's gross profit for the three months ended in Mar. 2024 was ¥628 Mil. YIFAN PHARMACEUTICAL CO's Revenue for the three months ended in Mar. 2024 was ¥1,326 Mil. Therefore, YIFAN PHARMACEUTICAL CO's Gross Margin % for the quarter that ended in Mar. 2024 was 47.37%.

YIFAN PHARMACEUTICAL CO had a gross margin of 47.37% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of YIFAN PHARMACEUTICAL CO was 57.23%. The lowest was 39.91%. And the median was 46.31%.


YIFAN PHARMACEUTICAL CO Gross Profit Historical Data

The historical data trend for YIFAN PHARMACEUTICAL CO's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

YIFAN PHARMACEUTICAL CO Gross Profit Chart

YIFAN PHARMACEUTICAL CO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,392.73 2,509.92 1,828.38 1,865.94 1,946.18

YIFAN PHARMACEUTICAL CO Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 457.78 523.17 501.74 463.48 628.06

Competitive Comparison of YIFAN PHARMACEUTICAL CO's Gross Profit

For the Drug Manufacturers - General subindustry, YIFAN PHARMACEUTICAL CO's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


YIFAN PHARMACEUTICAL CO's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, YIFAN PHARMACEUTICAL CO's Gross Profit distribution charts can be found below:

* The bar in red indicates where YIFAN PHARMACEUTICAL CO's Gross Profit falls into.



YIFAN PHARMACEUTICAL CO Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

YIFAN PHARMACEUTICAL CO's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=4068.107 - 2121.932
=1,946

YIFAN PHARMACEUTICAL CO's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=1325.969 - 697.907
=628

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,116 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

YIFAN PHARMACEUTICAL CO's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=628 / 1325.969
=47.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


YIFAN PHARMACEUTICAL CO  (SZSE:002019) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

YIFAN PHARMACEUTICAL CO had a gross margin of 47.37% for the quarter that ended in Mar. 2024 => Durable competitive advantage


YIFAN PHARMACEUTICAL CO Gross Profit Related Terms

Thank you for viewing the detailed overview of YIFAN PHARMACEUTICAL CO's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


YIFAN PHARMACEUTICAL CO (SZSE:002019) Business Description

Traded in Other Exchanges
N/A
Address
No. 50 Qinshan, Jincheng, Lin'an Economic Development Zone, Hangzhou, Zhejiang, CHN, 311300
YIFAN PHARMACEUTICAL CO LTD is a China-based company engaged in pharmaceutical innovation and manufacturing. The company focuses its activities on key areas like macromolecular biologics, high-value pharmaceuticals, and differentiated traditional Chinese medicines. The products of the company are F-627 for Neutropenia and Parkinson's disease, F-652 for acute alcoholic hepatitis, GvHD and acute pancreatitis and F-899 for growth deficiency. The company's products are sold in China and internationally.
Executives
Ye Yi Qun Director
Zhang Da Wei Executives
Geng Yu Hong Executives
Feng De Qi Directors, Directors, and Executives
Zhou Ben Yu Director
Lin Xing Directors, executives
Yu Hai Xia Executives
Cheng Xian Feng Directors, executives
Xu Guo Han Supervisors
Cao Shi Mei Director
Lin Guan Yu Director
Zhang Lian Chun Executives
Guo Xin Fu Director
Zheng Shi Ming Supervisors
Yin Hang Hua Executives

YIFAN PHARMACEUTICAL CO (SZSE:002019) Headlines

No Headlines